Last reviewed · How we verify

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) — Portfolio Competitive Intelligence Brief

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 8 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
TR-701 FA TR-701 FA phase 3 Oxazolidinone antibiotic Bacterial 70S ribosome Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Arpida AG · 1 shared drug class
  2. Clinica Universidad de Navarra, Universidad de Navarra · 1 shared drug class
  3. Fundacion Clinic per a la Recerca Biomédica · 1 shared drug class
  4. Merck Sharp & Dohme LLC · 1 shared drug class
  5. Pfizer · 1 shared drug class
  6. Shenzhen Third People's Hospital · 1 shared drug class
  7. University of Southern California · 1 shared drug class
  8. Wuhan Pulmonary Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA):

Cite this brief

Drug Landscape (2026). Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/trius-therapeutics-llc-a-subsidiary-of-merck-co-inc-rahway-new-jersey-usa. Accessed 2026-05-17.

Related